References
- Tam CS, O'Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
- Khouri IF, Saliba RM, Admirand J, . Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007;137:355–363.
- Hus I, Rolinski J, Tabarkiewicz J, . Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1621–1627.
- Biagi E, Rousseau R, Yvon E, . Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 2005;11:6916–6923.
- Wierda WG, Castro JE, Aguillon R, . A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010;24:1893–1900.
- Ramsay AG, Johnson AJ, Lee AM, . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
- Ferrajoli A, Lee BN, Schlette EJ, . Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
- Rock FL, Hardiman G, Timans JC, . A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998;95:588–593.
- Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.
- Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007;21:53–60.
- Jahrsdorfer B, Muhlenhoff L, Blackwell SE, . B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490–1499.
- Leonard JP, Link BK, Emmanouilides C, . Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13:6168–6174.
- Kanzler H, Barrat FJ, Hessel EM, . Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552–559.
- Liang X, Moseman EA, Farrar MA, . Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010;115:5041–5052.
- Zent CS, Smith BJ, Ballas ZK, . Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:211–217.